B.R.AI.N: AI-powered inspection for efficient pharmaceutical production

B.R.AI.N (Better Results through Artificial Intelligent Inspection) uses supervised machine learning to automate and optimize complex inspection processes. Deep learning models make reliable decisions and significantly improve inspection performance. The solution is flexibly integrable, even into existing systems.

Efficiency through reduced False Reject Rate (FRR)

A key benefit of B.R.AI.N is the significant reduction of the False Reject Rate (FRR) by up to 95%. Pharmaceutical manufacturers benefit from improved defect detection, lower costs, and significantly improved product quality. Costly re-inspections are avoided, and the efficiency of the production line is sustainably increased. The solution enables unrestricted high-speed inspection without compromising safety or efficiency and while maintaining full GxP compliance.

Flexible integration – even into existing systems

No pharmaceutical production line is the same. Körber analyzes the inspection conditions of an individual line to identify optimization opportunities, down to individual camera stations. This results in tailored solutions that perfectly combine traditional and AI-based inspection methods. B.R.AI.N can be integrated into new inspection machines or retrofitted into existing systems, using a minimally invasive approach and ready-to-use models that reduce inspection complexity.

Implementation is carried out without major production interruptions. Thanks to its modular architecture, camera stations can be gradually upgraded with AI technology, allowing production to respond flexibly and precisely to new requirements. Future adjustments and updates can also be made easily without the need for re-qualification.

“With B.R.AI.N, we offer our customers a powerful solution that not only ensures the quality of their products, but also substantially improves efficiency across the production line. The solution is fully compliant with the new Annex 22 and overall equipment effectiveness (OEE) increases significantly thanks to the consistently low False Reject Rate (FRR) and improved detection rates (DR),” explains Rupert Depner, VP Technical Sales Inspection, Business Area Pharma. 

Delivering the difference in pharma 

At Körber Business Area Pharma, we deliver the difference by empowering our customers with a holistic ecosystem approach. Our unique portfolio of end-to-end solutions ranges from machines – for aseptic processing, inspection, packaging and materials, and transport systems – to consulting, services, software, and digital and AI-driven solutions that serve as integrating layers to boost pharmaceutical manufacturing.  

We simplify processes, reduce risks and accelerate time-to-market – ensuring smooth collaboration along the entire pharmaceutical and biotech value chain. With deep industry expertise, we support global customers unlock new potential. Our solutions support a better quality of life for both present and future generations. 

www.koerber-pharma.com